H.C. Wainwright lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $5 from $18 and keeps a Buy rating on the shares following the Q4 results. The firm cites the company’s “significantly dilutive” March equity raise for the target cut.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- Promising Clinical Developments and Strategic Advancements Support Buy Rating for Tenaya Therapeutics
- Tenaya Therapeutics reports Q4 EPS (28c), consensus (31c)
- Insider Moves: Semtech, BioMarin, Yum!, Tenaya, Aurinia
- Biotech Alert: Searches spiking for these stocks today
- Tenaya Therapeutics Announces Public Offering Pricing